Neurotensin-induced tumor formation is regulated by micro RNA 133A-aftiphilin-dependent receptor recycling
This application discloses methods of treating, preventing, and diagnosing colorectal cancer and IBD in a subject comprising administering an effective dose of antisense miR-133α or AFTPH to the subject or detecting expression levels of miR-133α and AFTPH.
1. A method of treating inflammatory bowel disease in a subject in need thereof, the treatment comprising administering to the subject an effective dose of antisense miR-133α, wherein the antisense miR-133α is administered intracolonically or orally.
2. The method of claim 1 , wherein the antisense miR-133α is administered intracolonically.
3. The method of claim 1 , wherein the antisense miR-133α is a locked nucleic acid based miR-133α.
4. The method of claim 3 , wherein the locked nucleic acid based miR-133α is administered intracolonically.
5. The method of claim 1 , wherein the inflammatory bowel disease is selected from a group comprising Crohn's disease, ulcerative colitis, colitis, collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behcet's disease, and indeterminate colitis.
6. The method of claim 1 , wherein the subject is a mammal.
7. The method of claim 6 , wherein the subject is a human.
8. The method of claim 1 , wherein the antisense miR-133α comprises covalent internucleoside linkages.
9. The method of claim 1 , wherein the dose is effective to reduce intestinal inflammation.
10. The method of claim 1 , wherein the inflammatory bowel disease is ulcerative colitis.
11. The method of claim 1 , wherein the inflammatory bowel disease is Crohn's disease.
12. The method of claim 1 , wherein the antisense miR-133α is administered orally.
13. The method of claim 3 , wherein the locked nucleic acid based miR-133α is administered orally.